AtkinsRéalis to design expansion for vaccine manufacturing facility in Montreal
Plant Magazine
Innovation & Technology Operations Manufacturing infrastructure manufacturing OperationsThe expansion is part of Canada's Biomanufacturing and Life Sciences Strategy pandemic preparedness plan to domestically manufacture and supply vaccines.
AtkinsRéalis Group Inc., an engineering services and nuclear company, has won a mandate from Jubilant HollisterStier, a global pharmaceutical contract manufacturer, to provide detailed design for the expansion of their sterile injectable facility in Montreal. The expansion is part of Canada’s Biomanufacturing and Life Sciences Strategy pandemic preparedness plan to domestically manufacture and supply vaccines.
The facility upgrades will more than double its “fill and finish capacity,” which involves filling vaccine vials and preparing them for distribution, and enhance the existing 40,000 sq. ft. site to offer versatile manufacturing capabilities for various vaccine types and formats. This flexibility will enable the facility to respond to future health emergencies by producing a wide range of vaccines.
“Our life sciences and pharmaceutical capabilities are in demand and helping improve health outcomes in the communities we serve,” commented Ian L. Edwards, President and Chief Executive Officer, AtkinsRéalis. “We operationalize our purpose of engineering a better future for our planet and its people by working with clients in this space to ramp up their facilities to deliver cutting-edge medicine in a post-pandemic world. Having completed prior phases of work on this project for Jubilant HollisterStier, this new mandate is an endorsement of the quality of our service level, innovation, and expertise.”
AtkinsRéalis’ Industrial team will provide an integrated end-to-end solution for this phase of the project, including design and professional engineering services for the facility and its manufacturing processes. The new spaces are expected to be operational by late 2026.
The facility’s expansion is expected to generate contract development and manufacturing activities for other Quebec biopharmaceutical companies across the life sciences supply chain.
Jubilant HollisterStier’s expansion is partially funded by the Government of Canada’s Strategic Innovation Fund, as well as by the province of Quebec.
